Given the consensus that glucocorticoid dose reduction is imperative for reducing long-term disease burden and adverse metabolic effects, what degree of reduction should be considered in persons with CAH?

Name: Given the consensus that glucocorticoid dose reduction is imperative for reducing long-term disease burden and adverse metabolic effects, what degree of reduction should be considered in persons with CAH?
Uploaded: T00:00:00+00:00

CLICK HERE FOR CME CREDIT Back to Symposium

Given the consensus that glucocorticoid dose reduction is imperative for reducing long-term disease burden and adverse metabolic effects, what degree of reduction should be considered in persons with CAH??

Created by

Presenter

Ellen Seely, MD

Vice Chair, Faculty Development
Department of Medicine
Director of Clinical Research, Endocrinology, Diabetes and Hypertension Division
Brigham & Women's Hospital
Professor of Medicine
Harvard Medical School
Boston, MA